METABOLIC SYNDROME, ADIPONECTIN AND FAT ROS

The metabolic syndrome, a cluster of insulin resistance, elevated blood pressure, and atherogenic dyslipidemia, is a common basis of atherosclerosis. Accumulation of intra-abdominal visceral fat stands upstream of the metabolic syndrome. Adipose tissue expresses a variety of genes for bioactive secretory proteins conceptualized as adipocytokines. We discovered a novel adiposespecific protein named adiponectin from human fat cDNAs. Adiponectin circulates in the plasma and its serum level is decreased in visceral fat accumulation. Results of experimental and clinical researches have demonstrated that hypoadiponectinemia underlies the pathogenesis of multiple diseases related to visceral fat accumulation, including atherosclerosis, hypertension, cardiac failure, insulin resistance, diabetes, hepatic steatosis, inflammatory bowel disease, and cancers. Recently, we revealed fat-derived reactive oxygen species (fat ROS) as an upstream factor in the development of hypoadiponectinemia and metabolic syndrome. Intervention targeting visceral fat accumulation, hypoadiponectinemia and fat ROS should be the way to therapeuti

[1]  西原 承緒.  Effect of Adiponectin on Murine Colitis Induced by Dextran Sulfate Sodium , 2007 .

[2]  S. Kihara,et al.  Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. , 2006, Kidney international.

[3]  T. Funahashi,et al.  Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Kohjiro Ueki,et al.  Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. , 2006, The Journal of clinical investigation.

[5]  S. Kihara,et al.  Adiponectin Replenishment Ameliorates Obesity-Related Hypertension , 2006, Hypertension.

[6]  松本 仁.  Adiponectin deficiency exacerbates lipopolysaccharide/d-galactosamine-induced liver injury in mice , 2006 .

[7]  W. Willett,et al.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. , 2005, Journal of the National Cancer Institute.

[8]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[9]  A. Seftel.  Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. , 2005, The Journal of urology.

[10]  T. Mountokalakis,et al.  Plasma Adiponectin Levels and Five-Year Survival After First-Ever Ischemic Stroke , 2005, Stroke.

[11]  K. Çağlar,et al.  Prostate cancer and adiponectin. , 2005, Urology.

[12]  P. Scherer,et al.  Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome , 2005, Journal of internal medicine.

[13]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[14]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[15]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[16]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[17]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[18]  T. Ogihara,et al.  Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[19]  C. Mantzoros,et al.  Circulating adiponectin and endometrial cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[20]  C. Mantzoros,et al.  Adiponectin and breast cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  S. Kihara,et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[23]  S. Kihara,et al.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.

[24]  S. Kihara,et al.  Association of serum adiponectin levels with breast cancer risk. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.

[26]  T. Ogihara,et al.  Association of Hypoadiponectinemia With Impaired Vasoreactivity , 2003, Hypertension.

[27]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[28]  S. Kihara,et al.  Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. , 2003, Biochemical and biophysical research communications.

[29]  C. Mantzoros,et al.  Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. , 2003, The Journal of clinical endocrinology and metabolism.

[30]  Hitoshi Nishizawa,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.

[31]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[32]  M. Matsuda,et al.  Role of Adiponectin in Preventing Vascular Stenosis , 2002, The Journal of Biological Chemistry.

[33]  M. Matsuda,et al.  Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.

[34]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[35]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[36]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[37]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[38]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[39]  T. Funahashi,et al.  Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. , 2001, Diabetes.

[40]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[41]  NoriyukiOuchi,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[42]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[43]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[44]  T Nakamura,et al.  An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[45]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[46]  S. Kihara,et al.  Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. , 1999, Internal medicine.

[47]  Y. Matsuzawa,et al.  Analysis of an expression profile of genes in the human adipose tissue. , 1997, Gene.

[48]  Y. Matsuzawa,et al.  Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. , 1997, Diabetes/metabolism reviews.

[49]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[50]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[51]  T Nakamura,et al.  Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.

[52]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[53]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[54]  P. Björntorp,et al.  Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. , 1984, British medical journal.

[55]  A. Kissebah,et al.  Relation of Body Fat Distribution to Metabolic Complications of Obesity , 1982 .

[56]  大内 乗有.  Novel modulator for endothelial adhesion molecules : Adipocyte-derived plasma protein adiponectin , 2001 .

[57]  N. Kaplan.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[58]  F. Terry.  Human obesity. , 1987, Annals of the New York Academy of Sciences.

[59]  Y. Matsuzawa,et al.  Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. , 1987, Metabolism: clinical and experimental.